Joseph W. Eschbach, John W. Adamson Kidney International

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Volume 59, Issue 2, Pages (February 2001)

Pathophysiology of renal fluid retention

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

Volume 54, Issue 2, Pages (August 1998)

Volume 62, Issue 3, Pages (September 2002)

Erythropoietin should be part of congestive heart failure management

Beta blockers in the management of chronic kidney disease

Iron indices: What do they really mean?

Iron status and iron supplementation in peritoneal dialysis patients

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Erythropoietin should be part of congestive heart failure management

Volume 56, Pages S95-S98 (November 1999)

End-stage renal disease in developing countries

Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis James F. Medcalf, Kevin P.G.

Volume 83, Issue 3, Pages (March 2013)

Stem cells for kidney repair: useful tool for acute renal failure?

Volume 64, Pages S72-S77 (November 2003)

Volume 56, Issue 3, Pages (September 1999)

Volume 62, Issue 3, Pages (September 2002)

Continuous renal replacement therapy in the critically ill patient

Progression of renal failure and hypertensive nephrosclerosis

Volume 54, Issue 2, Pages (August 1998)

Pathophysiology of renal fluid retention

Francesco Paolo Schena Kidney International

Kamyar Kalantar-Zadeh Kidney International

Volume 76, Pages S50-S99 (August 2009)

Volume 70, Pages S21-S25 (December 2006)

G. Murcutt, J. Edwards, J. Boakye, A. Davenport Kidney International

A new era in phosphate binder therapy: What are the options?

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 70, Issue 11, Pages (December 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

Edmund G. Lowrie Kidney International

Prevention of renal failure: The Malaysian experience

Study of Heart and Renal Protection (SHARP)

Blood pressure targets in hemodialysis patients

Recent experience with high-dose intravenous iron administration

Volume 76, Issue 6, Pages (September 2009)

Francesco Locatelli, Lucia Del Vecchio Kidney International

Volume 64, Pages S72-S77 (November 2003)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 79, Issue 3, Pages (February 2011)

Nephrology in Latin America, with special emphasis on Brazil

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

Counteracting progression of renal disease: A look into the future

Lynda Anne Szczech, Ira L. Lazar Kidney International

Erythropoietin and iron

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 55, Issue 5, Pages (May 1999)

Wei-Teing Chen, Horng-Chin Yan, Fu-Chiu Yu Kidney International

Current status of maintenance hemodialysis in Beijing, China

Phosphate binders on iron basis: A new perspective?

Clinical benefits of slowing the progression of renal failure

Total hip bone mass predicts survival in chronic hemodialysis patients

The Danish Renal Biopsy Register

Volume 63, Issue 3, Pages (March 2003)

Volume 80, Issue 10, Pages (November 2011)

Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction Malcolm F. Hand, William G. Haynes, David J.

Volume 60, Issue 6, Pages (December 2001)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Renal replacement therapy in Latin America

Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation A.K. Singh, D.W. Coyne,

Volume 59, Issue 2, Pages (February 2001)

Strategies for iron supplementation: Oral versus intravenous

Evaluation of the Losartan in Hemodialysis (ELHE) Study

Presentation transcript:

Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy Joseph W. Eschbach, John W. Adamson Kidney International Volume 55, Pages S35-S43 (March 1999) DOI: 10.1046/j.1523-1755.1999.055Suppl.69035.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 The amount of nonerythroid iron turnover in patients on chronic hemodialysis related to their serum iron values (A) and percentage transferrin saturation (B; unpublished observations). Kidney International 1999 55, S35-S43DOI: (10.1046/j.1523-1755.1999.055Suppl.69035.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Decline in serum ferritin levels during three to four years of rHuEPO therapy in 17 hemodialysis patients42. Symbols are: (○) iron excess, N = 6; (•) normal stores, N = 11. Kidney International 1999 55, S35-S43DOI: (10.1046/j.1523-1755.1999.055Suppl.69035.x) Copyright © 1999 International Society of Nephrology Terms and Conditions